Literature DB >> 31774502

An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS).

Daniel E Harris1,2,3, Daniel Thayer4, Ting Wang5, Caroline Brooks5, Geoff Murley4, Mike Gravenor4, Nathan R Hill6, Steven Lister7, Julian Halcox1,2,3.   

Abstract

AIMS: In patients with non-valvular atrial fibrillation prescribed warfarin, the UK National Institute of Health and Care Excellence (NICE) defines poor anticoagulation as a time in therapeutic range (TTR) of <65%, any two international normalized ratios (INRs) within a 6-month period of ≤1.5 ('low'), two INRs ≥5 within 6 months, or any INR ≥8 ('high'). Our objectives were to (i) quantify the number of patients with poor INR control and (ii) describe the demographic and clinical characteristics associated with poor INR control. METHOD AND
RESULTS: Linked anonymized health record data for Wales, UK (2006-2017) was used to evaluate patients prescribed warfarin who had at least 6 months of INR data. 32 380 patients were included. In total, 13 913 (43.0%) patients had at least one of the NICE markers of poor INR control. Importantly, in the 24 123 (74.6%) of the cohort with an acceptable TTR (≥65%), 5676 (23.5%) had either low or high INR readings at some point in their history. In a multivariable regression female gender, age (≥75 years), excess alcohol, diabetes heart failure, ischaemic heart disease, and respiratory disease were independently associated with all markers of poor INR control.
CONCLUSION: Acceptable INR control according to NICE standards is poor. Of those with an acceptable TTR (>65%), one-quarter still had unacceptably low or high INR levels according to NICE criteria. Thus, only using TTR to assess effectiveness with warfarin has the potential to miss a large number of patients with non-therapeutic INRs who are likely to be at increased risk.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Atrial fibrillation; Pharmacoepidemiology; Warfarin

Mesh:

Substances:

Year:  2021        PMID: 31774502      PMCID: PMC7811400          DOI: 10.1093/ehjcvp/pvz071

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  29 in total

1.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

2.  The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin.

Authors:  A John Camm
Journal:  Eur Heart J       Date:  2009-09-21       Impact factor: 29.983

3.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

4.  Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care.

Authors:  Faisal Aziz; Mary Corder; Jaclyn Wolffe; Anthony J Comerota
Journal:  J Vasc Surg       Date:  2011-07-13       Impact factor: 4.268

5.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.

Authors: 
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

6.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

7.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  The SAIL Databank: building a national architecture for e-health research and evaluation.

Authors:  David V Ford; Kerina H Jones; Jean-Philippe Verplancke; Ronan A Lyons; Gareth John; Ginevra Brown; Caroline J Brooks; Simon Thompson; Owen Bodger; Tony Couch; Ken Leake
Journal:  BMC Health Serv Res       Date:  2009-09-04       Impact factor: 2.655

10.  The SAIL databank: linking multiple health and social care datasets.

Authors:  Ronan A Lyons; Kerina H Jones; Gareth John; Caroline J Brooks; Jean-Philippe Verplancke; David V Ford; Ginevra Brown; Ken Leake
Journal:  BMC Med Inform Decis Mak       Date:  2009-01-16       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.